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BACKGROUND: KIT exon 11 mutations are observed in 60% of gastrointestinal stromal tumours (GIST). Exon 11 codes for residues
Tyr568 and Tyr570, which play a major role in signal transduction and degradation of KIT. Our aim was to compare the outcome of
patients with deletion of both Tyr568–570 (delTyr) and the most frequent deletion delWK557–558 (delWK).
METHODS: Pathology and clinical characteristics of 68 patients with delTyr (n¼26) or delWK (n¼42) were reviewed and compared.
RESULTS: GISTs with delTyr were more frequently extragastric than those with delWK (69 vs 26%, Po0.0005). After curative surgery,
median relapse-free survival were 10.8 and 11.1 months for patients with delTyr (n¼14) and delWK (n¼29), respectively
(P¼0.92). All patients treated with imatinib for a non-resectable or metastatic GIST had an objective response (n¼15) or a stable
disease (n¼21) as best response, regardless of mutation. Median progression-free survival with imatinib were 21.9 and 18.9 months
for patients with GIST with delTyr (n¼14) and delWK (n¼22), respectively (P¼0.43).
CONCLUSION: In this large retrospective series, the type of KIT exon 11 mutation was correlated with the origin of GIST, but not with
prognosis or response to imatinib.
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Gastrointestinal stromal tumours (GISTs) are the most frequent
mesenchymal tumours of the digestive tract and occur typically in
the stomach for two-third or in the small intestine for 25% in most
series (Emile et al, 2004). Gain of function mutations of either KIT
or platelet-derived growth factor receptor alpha polypeptide
(PDGFRA) receptor tyrosine kinases play a critical role in GIST
pathogenesis, and are found in 85% of GISTs (Rubin et al, 2007).
Many types of gain of function mutations of KIT and PDGFRA
have been described in GISTs, but 60% occurred within the exon
11 of KIT (Corless et al, 2004; Emile et al, 2004), which comprises
33 codons (codons 550–582). The two tyrosines Tyr568 and
Tyr570, first residues to be phosphorylated during activation, are
consensus sites for binding of Src family kinases and could be
implicated in activation of different signalling pathways (Roskoski,
2005). More than 90 mutations of exon 11 have been published,
and consist in insertions, substitutions and deletions; however,
delWK557–558, in the proximal part of exon 11, is the most
frequent, accounting for 8–25% of KIT exon 11 mutations. Others
deletions, in the distal part of the exon, include in particular
deletions of Tyr568 and/or Tyr570, and may thus have more
specific effects on KIT signalling pathways and degradation. Such
deletions account for 3–8% of exon 11 mutations in published
series (Ernst et al, 1998; Taniguchi et al, 1999; Debiec-Rychter
et al, 2004, 2006; Wardelmann et al, 2004; Martin et al, 2005;
Penzel et al, 2005; Andersson et al, 2006; Emile et al, 2006;
DeMatteo et al, 2008).
After surgical resection, the type of KIT mutations may be a
prognostic factor of relapse. KIT exon 11 deletions and deletions
affecting codons 557–558 of KIT exon 11 were described to be
independent adverse prognostic factors in patients with GIST
(Wardelmann et al, 2003; Martin et al, 2005; DeMatteo et al, 2008).
Conversely, in another study, GISTs in which the last part of exon
11 (codons 562–579) was deleted were most frequently associated
with malignancy than GISTs with deletion of the first part of exon
11 (codons 550–561; Emile et al, 2004, 2006). So, the prognostic
value of some types of KIT exon 11 mutations for risk of relapse is
still debated. The mutational status of KIT or PDGFRA is predictive
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sof clinical response to imatinib (Glivec, Gleevec, Novartis, Basel,
Switzerland) and best results are obtained in patients with GISTs
harbouring KIT exon 11 mutations (Heinrich et al, 2003; Debiec-
Rychter et al, 2006). Nevertheless, the role of the type of KIT exon
11 mutations for the response and survival under imatinib remains
to be determined.
Thus, to better understand the prognostic significance of the
type of KIT exon 11 deletions, we have compared the clinical
characteristics and outcome of patients with GIST and deletion of
both Tyr568 and Tyr570 with the most frequent deletion of KIT
exon 11, delWK557–558.
MATERIALS AND METHODS
Patient selection
From database of two French pathology departments which detect
KIT and PDGFRA mutations in routine practice (Ambroise Pare
Hospital, Boulogne; Bergonie Institute, Bordeaux, France), we
searched retrospectively for all consecutive patients with GIST and
with either delWK or deletions including both residues Tyr568 and
Tyr570 (delTyr). Mutations within exon 9, 11, 13 and 17 of KIT and
within exon 12 and 18 of PDGFRA were detected as previously
described (Emile et al, 2002, 2004; Heinrich et al, 2003; Hostein
et al, 2006).
Pathology
All samples were obtained before treatment with imatinib.
Paraffin-embedded samples were independently analysed by at
least two pathologists. For resected GIST, largest tumour diameter
and mitotic count per 50 high-power fields (HPF) were evaluated
after surgery in each case, as recommended by international
criteria and used to evaluate the risk of GIST malignancy (Fletcher
et al, 2002; Miettinen and Lasota, 2006). Immunohistochemistry
was performed with anti-CD117 (A-4502, polyclonal; DAKO,
Copenhagen, Denmark).
Clinical data and survival analysis
Medical records of all patients were retrospectively reviewed.
Response rates to imatinib were evaluated by spiral computerised
tomography according to the RECIST criteria. The relapse-free
survival (RFS) was defined as the time between the date of curative
surgery and the date of relapse. The progression-free survival
(PFS) was defined as the time between the first day of imatinib and
the date of progression or death. Overall survival (OS) under
imatinib was defined as the time between the first day of imatinib
and the date of death or last follow-up.
Statistical analysis
Results are expressed as medians and ranges. The cut-off date for
the final analysis was 15 January 2008. We used Student’s t-test to
compare quantitative data in univariate analyses and w
2-tests were
used for qualitative data. We estimated RFS, PFS and OS using the
Kaplan–Meier method, and we used log-rank tests to compare the
survival curves (Kaplan and Meier, 1958). SAS software v 9.1 (SAS
Institute Inc., Cary, NC, USA) was used for all statistical analysis.
Figure 1 Type and position of deletions including both tyrosines Tyr568 and Tyr570.
Table 1 Clinical and pathologic characteristics of patients according to
the type of exon 11 deletion
Type of exon 11 deletion DelWK557–558 DelTyr
Number of patients 42 26
Age at diagnosis (years)
a 58 (19–93) 63 (44–86)
Sex
Male 22 (52%) 16 (62.5%)
Female 20 (48%) 10 (37.5%)
Stage of the disease at diagnosis
Resectable 32 (76%) 16 (61%)
Non-resectable 2 (5%) 1 (4%)
Metastatic 8 (19%) 9 (35%)
Location of the primary tumour
Stomach 31 (74%) 8 (31%)
Small Intestine 8 (19%) 15 (58%)
Colon/rectum 3 (7%) 3 (11%)
Histologic phenotype
Spindle type 31 (74%) 21 (80%)
Epithelioid type 3 (7%) 1 (4%)
Mixed type 8 (19%) 4 (15%)
Percent of necrosis
0% 15 (36%) 9 (35%)
o50% 23 (55%) 9 (35%)
450% 2 (5%) 6 (23%)
Non-evaluable 2 (5%) 2 (8%)
Positive CD117 staining 42 (100%) 26 (100%)
aMedian and range.
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sRESULTS
Mutation, clinical and pathologic characteristics
A total of 68 patients with GIST, diagnosed between 1985 and 2007,
and all CD117 positive, were retrieved. DelWK and delTyr
accounted for 18% (34/185) and 10% (19/185) of KIT exon 11
mutations in Ambroise Pare ´0s series, respectively. Out of the 26
delTyr mutations, 8 also involved both amino acids 557 and 558,
and one involved the amino acid 558. Details of delTyr mutations
are summarised in Figure 1.
GISTs with delTyr were more frequently extragastric than those
with delWK (69 vs 26%, Po0.0005), whereas other clinical and
tumour characteristics were not different (Table 1). After exclusion
of the 8 GISTs with delTyr including the 2 amino acids 557 and
558, GISTs with delTyr (n¼18) were still more frequently
extragastric (P¼0.0031).
Distribution of patients according to the outcome and the type
of KIT exon 11 deletion is described in Figure 2.
Relapse-free survival
Mitotic count, tumour size and risk classifications were not
different between patients with delWK and those with delTyr
(Table 2). At the date of cut-off, median time since curative surgery
was 5.1 years (range 0.4–21.9 years). Three patients with delWK
and two patients with delTyr had been included in an adjuvant
prospective trial with imatinib, and were excluded of RFS analysis.
Median RFS were 11.1 months (95% CI: 9.4–66.6) and 10.8 months
(95% CI: 7.1–57.7; P¼0.92; Figure 3A), respectively. Results were
not modified after exclusion of the eight GISTs with delTyr
including the two amino acids 557 and 558 (P¼0.45).
Objective response and survival under imatinib
During follow-up, 22 patients with delWK and 14 patients with
delTyr received imatinib (Figure 2). Out of these 36 patients, 26
(72%) had been included and evaluated in a prospective trial. At
the date of cut-off, median time since imatinib beginning was 4.7
years (range 0.7–6.8 years).
Objective responses to imatinib were not different between
patients with delWK and those with delTyr (Table 3). Median PFS
under imatinib were 18.9 months (95% CI: 12.6– ) for patients with
delWK and 21.9 months (95% CI: 16.1–37.4) for patients with
delTyr (P¼0.43; Figure 3B). Median OS since imatinib beginning
were 31.4 months (95% CI: 19.7–) and 38.6 months (95% CI: 35.4–
45.3; P¼0.31; Figure 3C), respectively. After exclusion of the 8
GISTs with delTyr including the two amino acids 557 and 558,
results were not modified for median PFS (P¼0.60) and OS
(P¼0.39).
DISCUSSION
KIT exon 11 mutations are present in the majority of GISTs. Many
different types of mutations have been published, some of which
delete residues Tyr568 and Tyr570, which play an important role in
KIT signal transduction. Thus, we compared these mutations
(delTyr) with the most frequent mutation of KIT exon 11 in GISTs
(delWK557–558). Analysis of our large series of patients shows
that GISTs with delWK are mainly gastric, whereas GISTs with
delTyr are mainly intestinal. However, GISTs with these mutations
had identical prognosis after curative surgery and response to
imatinib treatment.
Previous studies described that the GIST’s location was
associated with type of mutation. GISTs with KIT exon 9 mutation
arise predominantly in small intestine and colon, and those with
PDGFRA mutations most often originate from the stomach (Emile
et al, 2004; Wardelmann et al, 2004; Penzel et al, 2005). Our results
show that GISTs with delTyr arise in small intestine, colon or
rectum in about 70% of cases, whereas those with delWK557–558
occur in stomach in about 75% of cases, and this difference was
highly significant. This suggests possible different types of
Patients with GISTs with
DelWK557-558 / DelTyr
42 / 26 
Resectable GIST with curative surgery
32 / 16 
Non-resectable or metastatic GISTs at diagnosis
10 / 10
Patients included
in relapse-free
survival analysis 
Patients included
in progression-free
survival analysis 
Adjuvant treatment with imatinib
3 / 2 
29 / 14
Relapse
17 / 9
No relapse
12 / 5
No Imatinib
5 / 5
Death
7 / 5
Secondary resistance to imatinib during follow-up
11 / 6 
Imatinib
22 / 14
Death
4 / 4
Death
3 / 0
Non-resectable or metastatic
GISTs during follow-up
27 / 19
Figure 2 Distribution of the patients according to the outcome.
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soncogenic events driving KIT mutations in the different parts of
the digestive tract.
Recently, some studies reported that GISTs with delWK557–558
have an increased risk of relapse after curative surgery (Wardelmann
et al, 2003; Martin et al, 2005; DeMatteo et al, 2008). In our study,
GISTs with delWK557–558 and GISTs with delTyr did not differ
for the risk of relapse after curative surgery and both convey a
poor prognosis. According to tumour location, independently of
the risk stage, a relapse occurred in 56% (14/25) and 75% (3/4) of
gastric GISTs with delWK and delTyr, and in 40% (2/5) and 66.7%
(6/9) of intestinal GISTs, respectively. So, GISTs with these
02 0 4 0 6 0
Time (months)
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Figure 3 (A) Relapse-free survival according to the type of exon 11
deletion. (B) Progression-free survival under imatinib according to the type
of exon 11 deletion. (C) Overall survival under imatinib according to the
type of exon 11 deletion.
Table 3 Outcome under imatinib according to the type of exon 11 deletion
Type of exon 11 deletion DelWK557–558 DelTyr
Treatment by imatinib for patients with a non-resectable or metastatic GIST during follow-up (n¼27) (n¼19)
No 5 (19%) 5 (26%)
Yes 22 (81%) 14 (74%)
Best response under imatinib (RECIST criteria)
Complete response 1 (5%) 1 (7%)
Partial response 9 (41%) 4 (29%)
Stable disease 12 (55%) 9 (64%)
Progressive disease 00
Number of patients who had secondary resistance to imatinib during follow-up 11 (50%) 6 (43%)
Number of patients dead at the end of follow-up 14 (33%) 10 (38%)
Cause of death
GIST 8 (57%) 8 (80%)
Others 6 (43%) 2 (20%)
Table 2 Prognostic factors after curative surgery and outcome of
patients according to the type of exon 11 deletion
Type of exon 11 deletion DelWK557–558 DelTyr
Number of resected GISTs at diagnosis 32 16
Largest tumour diameter (cm)
o2 1 (3%) 0
2–5 7 (22%) 6 (37.5%)
5–10 13 (41%) 2 (12.5%)
410 11 (34%) 8 (50%)
Mitotic count per 50 HPF
o5 8 (25%) 8 (50%)
6–10 4 (12.5%) 2 (12.5%)
410 20 (62.5%) 6 (37.5%)
Risk stage (Fletcher et al, 2002)
Very low 0 0
Low 2 (6%) 4 (25%)
Intermediate 4 (13%) 2 (12.5%)
High 26 (81%) 10 (62.5%)
Risk stage (Miettinen and Lasota, 2006)
Very low 2 (6%) 1 (6%)
Low 3 (9%) 3 (19%)
Intermediate 6 (19%) 1 (6%)
High 20 (63%) 11 (69%)
Non-evaluable 1 (3%) 0
Relapse after curative surgery for patients with a resectable GIST at diagnosis (number
of patients)
No 15 (47%) 7 (44%)
Yes 17 (53%) 9 (56%)
Relapse location after curative surgery
a
Peritoneum 13 (76%) 8 (89%)
Liver 5 (29%) 5 (56%)
Lung 1 (6%) 0
aSome patients had two sites of relapse.
GISTs with KIT exon 11 deletion
J-B Bachet et al
10
British Journal of Cancer (2009) 101(1), 7–11 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
smutations seem to have the same worse prognosis and gastric
GIST with exon 11 mutations may be of the same poor prognosis
as small bowel or large bowel GIST actually.
The outcome of non-resectable and metastatic GISTs with
delWK and delTyr under imatinib is similar in terms of response
rates, PFS and OS. All patients included in our study had an
objective response or a stable disease under imatinib, and median
PFS were of about 20 months. These results are concordant with
results of published phase III studies (Heinrich et al, 2003; Debiec-
Rychter et al, 2006).
In this large retrospective series, the type of KIT exon 11
mutation differed according to primary site, with delWK originat-
ing from the stomach, whereas those with delTyr from the
intestine. However, GISTs with these mutations had the same
prognosis after curative surgery and under imatinib.
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